Venture_Socks_RZ_RGB_300dpi(2)_edited.pn
icon-prizes.png

WINNERS

orange arrows.png

Inositec

2015

Health & Nutrition

2000_W1_Carbofix.png
Sensirion_edited.jpg

Inositec AG is developing first-in-class treatments for soft tissue calcification disorders based on its proprietary Inositune™ platform of inositol phosphate (IP6) analogs. The company’s lead programs address vascular and renal calcification disorders, including orphan indications.